Amneal Pharmaceuticals (NYSE:AMRX) received a $5.00 price target from stock analysts at Barclays in a report issued on Thursday, TipRanks reports. The brokerage currently has a “hold” rating on the stock. Barclays‘s price objective would suggest a potential upside of 35.14% from the stock’s current price.
Several other equities analysts have also issued reports on the stock. Zacks Investment Research lowered shares of ExlService from a “hold” rating to a “sell” rating in a report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and set a $130.00 price objective (up from $116.00) on shares of Zoetis in a report on Wednesday, June 12th. Royal Bank of Canada lowered shares of Amneal Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $11.00 to $6.00 in a report on Thursday. SunTrust Banks lifted their price objective on shares of Willis Towers Watson from $210.00 to $225.00 and gave the company a “buy” rating in a report on Thursday. They noted that the move was a valuation call. Finally, BMO Capital Markets lifted their price objective on shares of Sun Life Financial from C$58.00 to C$60.00 in a report on Friday, May 10th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $14.27.
AMRX stock traded down $0.35 during trading on Thursday, hitting $3.70. 4,545,344 shares of the company’s stock traded hands, compared to its average volume of 1,746,422. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of 3.89, a P/E/G ratio of 0.23 and a beta of 1.50. The stock’s fifty day moving average price is $7.12. The company has a debt-to-equity ratio of 3.44, a current ratio of 2.11 and a quick ratio of 1.37. Amneal Pharmaceuticals has a 1 year low of $3.69 and a 1 year high of $24.48.
Amneal Pharmaceuticals (NYSE:AMRX) last issued its quarterly earnings data on Thursday, May 9th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.07). The business had revenue of $446.00 million for the quarter, compared to analysts’ expectations of $438.18 million. Amneal Pharmaceuticals had a negative net margin of 3.75% and a positive return on equity of 32.14%. Amneal Pharmaceuticals’s revenue for the quarter was up 4.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Amneal Pharmaceuticals will post 0.74 EPS for the current fiscal year.
In related news, VP Andrew S. Boyer acquired 19,000 shares of the company’s stock in a transaction dated Monday, May 13th. The shares were purchased at an average cost of $9.46 per share, with a total value of $179,740.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Pradeep Bhadauria acquired 7,000 shares of the company’s stock in a transaction dated Wednesday, May 15th. The shares were bought at an average cost of $8.48 per share, for a total transaction of $59,360.00. The disclosure for this purchase can be found here. Insiders acquired 41,000 shares of company stock worth $387,300 over the last ninety days. Corporate insiders own 26.34% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Menta Capital LLC acquired a new position in Amneal Pharmaceuticals during the fourth quarter valued at $403,000. New York State Common Retirement Fund lifted its position in Amneal Pharmaceuticals by 27.3% during the first quarter. New York State Common Retirement Fund now owns 108,616 shares of the company’s stock valued at $1,539,000 after purchasing an additional 23,316 shares during the period. Meeder Asset Management Inc. lifted its position in Amneal Pharmaceuticals by 785.6% during the first quarter. Meeder Asset Management Inc. now owns 11,664 shares of the company’s stock valued at $166,000 after purchasing an additional 10,347 shares during the period. Norges Bank acquired a new position in Amneal Pharmaceuticals during the fourth quarter valued at $18,243,000. Finally, Principal Financial Group Inc. lifted its position in Amneal Pharmaceuticals by 30.4% during the fourth quarter. Principal Financial Group Inc. now owns 16,485 shares of the company’s stock valued at $223,000 after purchasing an additional 3,843 shares during the period. Institutional investors own 36.05% of the company’s stock.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Featured Story: What is channel trading?
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.